The effect of pharmacotherapy on the effectiveness of exposure therapy

Handbook of Exposure Therapies

Volumn , Issue , 2007, Pages 311-333

  Deacon, Brett ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954256008     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012587421-2/50015-6     Document Type: Chapter

References (76)

1. Addis M.E., Jacobson N.S. Reasons for depression and the process and outcome of cognitive-behavioral psychotherapies. Journal of Consulting and Clinical Psychology 1996, 64:1417-1424.
2. Addis M.E., Jacobson N.S. A closer look at the treatment rationale and homework compliance in cognitive therapy for depression. Cognitive Therapy and Research 2000, 24:313-326.
3. Barlow D.H., Craske M.G. Mastery of Your Anxiety and Panic 2000, Gray- wind Publications Inc./The Psychological Corporation, San Antonio,TX. 3rd ed.
4. Barlow D.H., Gorman J.M., Shear M.K., Woods S.W. Cognitive-behavioral therapy, imipra-mine, or their combination for panic disorder: A randomized controlled trial. Journal of the American Medical Association 2000, 283:2529-2536.
5. Beck A.T., Emery G., Greenberg R. Anxiety disorders and phobias: A cognitive perspective 1985, Basic Books, New York.
6. Biondi M., Picardi A. Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive-behavi A follow-up study. Psychotherapy and Psychosomatics 2003, 72:34-42.
7. Blomhoff S., Haug T.T., Hellstrom K., Holme I., Humble M., Wold J.E. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. British Journal of Psychiatry 2001, 179:23-30.
8. Bouton M.E. Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biological Psychiatry 2002, 52:976-986.
9. Bruce T.J., Spiegel D.A., Hegel M.T. Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria Dartmouth studies. Journal of Consulting and Clinical Psychology 1999, 67:151-156.
10. Cottraux J., Mollard E., Bouvard M., Marks I., Sluys M., Nury A.M., Douge R., Ciadella P. Controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology 1990, 5:17-30.
11. Cottraux J., Note I.D., Cungi C., Legeron P., Heim F., Chneiweiss L., Bernard G., Bouvard M. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. British Journal of Psychiatry 1995, 167:635-641.
12. Davidson J.R., Foa E.B., Huppert J.D., Keefe F.J., Franklin M.E., Compton J.S., Zhao N., Connor K.M., Lynch T.R., Gadde K.M. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry 2004, 61:1005-1013.
13. de Beurs E., van Balkom A.J.L.M., Lange A., Koele P., van Dyck R. Treatment of panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in. American Journal of Psychiatry 1995, 152:683-691.
14. Deacon B.J., Abramowitz J.S. Cognitive and behavioral treatments for anxiety disorders: A review of meta-analytic findings. Journal of Clinical Psychology 2004, 60:429-441.
15. Echeburua E., De Corral P., Bajos E.G., Borda M. Interactions between self-exposure and alprazolam in the treatment of agoraphobia without current panic: An exploratory study. Behavioural and Cognitive Psychotherapy 1993, 21:219-238.
16. Fedoroff I.C., Taylor S. Psychological and pharmacological treatments of social phobia: A meta analysis. Journal of Clinical Psychopharmacology 2001, 21:311-324.
17. Foa E.B., Franklin M.E., Moser J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination?. Biological Psychiatry 2002, 10:987-997.
18. Foa E.B., Kozak M.J. Emotional processing of fear: Exposure to corrective information. Psychological Bulletin 1986, 99:20-35.
19. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., Huppert J.D., Kjernisted K., Rowan V., Schmidt A.B., Simpson H.B., Tu X. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treat-ment of obsessive-compulsive disorder. American Journal of Psychiatry 2005, 162:151-161.
20. Foa E.B., Rauch S.A. Cognitive changes during prolonged exposure versus prolonged expo-sure plus cognitive restructuring in female assault survivors with posttraumatic stress diso. Journal of Consulting and Clinical Psychology 2004, 72:879-884.
21. Franklin M.E., Abramowitz J.S., Bux D.A., Zoellner L.A., Feeny N.C. Cognitive-behavior therapy with and without medication in the treatment of obsessive-compulsive disorder. Professional Psychology: Research and Practice 2002, 33:162-168.
22. Goldstein A.J., Chambless D.L. A reanalysis of agoraphobia. Behavior Therapy 1978, 9:47-59.
23. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability. Archives of General Psychiatry 1989, 46:1006-1011.
24. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale: II. Validity. Archives of General Psychiatry 1989, 46:1012-1016.
25. Gould R.A., Buckminster S., Pollack M.H., Otto M.W., Yap L. Cognitive-behavioral and pharmacological treatment for social phobia: A meta-analysis. Clinical Psychology: Science and Practice 1997, 4:291-306.
26. Gould R.A., Otto M.W., Pollack M.H. A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review 1995, 8:819-844.
27. Gould R.A., Otto M.W., Pollack M.H., Yap L. Cognitive behavioral and pharmacologi-cal treatment of generalized anxiety disorder: A preliminary meta-analysis. Behavior Therapy 1997, 28:285-305.
28. Haug T.T., Blomhoff S., Hellstrom K., Holme I., Humble M., Madsbu H.P., Wold J.E. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. British Journal of Psychiatry 2003, 182:12-18.
29. Hegel M.T., Ravaris C.L., Ahles T.A. Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder. Behavior Therapy 1994, 25:183-195.
30. Heimberg R.G., Liebowitz M.R., Hope D.A., Schneier F.R., Holt C.S., Welkowitz L.A., Juster H.R., Campeas R., Bruch M.A., Cloitre M., Fallon B., Klein D.F. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Archives of General Psychiatry 1998, 55:1133-1141.
31. Hohagen F., Winkelmann G., Rasche-Rauchle H., Hand I., Konig A., Munchau N., Hiss H., Geiger-Kabisch C., Kappler C., Schramm P., Rey E., Aldenhoff J., Berger M. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: Results of a multicentre study. British Journal of Psychiatry 1998, 173(35):71-78.
32. Hunt M., Gibbons L., Paraison H., Rabik C. Report of the committee on academic training: Medical specialty training on panic disorder. Behavior Therapist 2004, 27:18-20.
33. Krystal J.H., Deutsch D.N., Charney D.S. The biological basis of panic disorder. Journalof Clinical Psychiatry 1996, 57(suppl. 6):23-31.
34. Liebowitz M.R., Heimberg R.G., Schneier F.R., Hope D.A., Davies S., Holt C.S., Goetz D., Juster H.R., Lin S.H., Bruch M.A., Marshall R.D., Klein D.F. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depression and Anxiety 1999, 10:89-98.
35. Lydiard R.B., Brawman-Mintzer O., Ballenger J.C. Recent developments in the psychophar-macology of anxiety disorders. Journal of Consulting and Clinical Psychology 1996, 64:660-668.
36. Marks I.M., Gray S., Cohen D., Hill R., Mawson D., Ramm E., Stern R.S. Imipramine and brief therapist-aided exposure in agoraphobics having self-exposure homework. Archives of General Psychiatry 1983, 40:153-162.
37. Marks I.M., Swinson R.P., Basoglu M., Noshirvani H., O'Sullivan G., Lelliott P.T., Kirby M., McNa-mee G., Sengun S., Wickwire K. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled study. British Journal of Psychiatry 1993, 162:776-787.
38. Mavissakalian M., Michelson L. Relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry 1986, 47:117-122.
39. Mavissakalian M., Michelson L. Two-year follow-up of exposure and imipramine treatment of agoraphobia. American Journal of Psychiatry 1986, 143:1106-1112.
40. Mavissakalian M., Michelson L., Dealy R.S. Pharmacological treatment of agorapho-bia: Imipramine versus imipramine with programmed practice. British Journal of Psychiatry 1983, 143:348-355.
41. Mavissakalian M., Perel J., Guo S. Specific side effects of long-term imipramine management of panic disorder. Journal of Clinical Psychopharmacology 2002, 22:155-161.
42. McLean P.D., Whittal M.L., Thordarson D.S., Taylor S., Söchting I., Koch W.J., Paterson R., Ander-son K.W. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. Journal of Consulting and Clinical Psychology 2001, 69:205-214.
43. Michelson L., Mavissakalian M., Marchione K. Cognitive-behavioral treatments of ago-raphobia: Clinical, behavioral, and psychophysiological outcome. Journal of Consulting and Clinical Psychology 1985, 53:913-925.
44. Mystkowski J.L., Mineka S., Vernon L.L., Zinbarg R.E. Changes in caffeine states enhance return of fear in spider phobia. Journal of Consulting and Clinical Psychology 2003, 71:243-250.
45. Oei T.P.S., Llamas M., Evans L. Does concurrent drug intake affect the long-term outcome of group cognitive behaviour therapy in panic disorder with or without agoraphobia?. Behaviour Research and Therapy 1997, 35:851-857.
46. Otto M.W., Hinton D., Korbly N.B., Chea A., Phalnarith B., Gershuny B.S., Pollack M.H. Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: A pilot study of combination treatment with cognitive-behavior vs. sertraline alone. Behaviour Research and Therapy 2003, 41:1271-1276.
47. Otto M.W., Penava S.J., Pollock R.A., Smoller J.W. Cognitive-behavioral and pharmacologi- cal perspectives on the treatment of post-traumatic stress disorder. Challenges in clinical practice: Pharmacologic and strategies 1996, 219-260. Guilford Press, NewYork. M.H. Pollack, M.W. Otto, J.F. Rosenbaum (Eds.).
48. Otto M.W., Pollack M.H., Sabatino S.A. Maintenance of remission following cognitive-behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment. Behavior Therapy 1996, 27:473-482.
49. Otto M.W., Pollack M.H., Sachs G.S., Reiter S.R., Meltzer-Brody S., Rosenbaum J.F. Dis-continuation of benzodiazepine treatment: Efficacy of cognitive-behavioral therapy for patients with panic disorder. American Journal of Psychiatry 1993, 150:1485-1490.
50. Otto M.W., Smits J.A.J., Reese H.E. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. Clinical Psychology: Science and Practice 2005, 12:72-86.
51. Otto M.W., Tuby K.S., Gould R.A., McLean R.Y.S., Pollack M.H. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry 2001, 158:1989-1992.
52. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Stu randomized controlled trial. Journal of the American Medical Association 2004, 292:1969-1976.
53. Pigot T.A. OCD: Where the serotonin selectivity story begins. Journal of Clinical Psychiatry 1996, 57(suppl. 6):11-20.
54. Power K.G., Simpson R.J., Swanson V., Wallace L.A. Controlled comparison of pharmaco-logical and psychological treatment of generalized anxiety disorder in primary care. British Journal of General Practice 1990, 40:2889-3294.
55. Powers M.B., Smits J.A.J., Telch M.J. Disentangling the effects of safety-behavior utilization and safety-behavior availability during exposure-based treatment: A placebo-controlled trial. Journal of Consulting and Clinical Psychology 2004, 72:448-454.
56. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., Hodges L., Davis M. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic indi-viduals to facilitate extinction of fear. Archives of General Psychiatry 2004, 61:1136-1144.
57. Salkovskis P.M. The importance of behaviour in the maintenance of anxiety and panic: A cogni-tive account. Behavioural Psychotherapy 1991, 19:6-19.
58. Schmidt N.B., Koselka M., Woolaway-Bickel K. Combined treatments for phobic anxiety disorders. Combined treatment for mental disorders: A guide to psychological and pharmacological interventions 2001, 81-110. American Psycho- logical Association, Washington, D.C., US. M. Sammons, N.B. Schmidt (Eds.).
59. Schmidt N.B., Woolaway-Bickel K., Trakowski J.H., Santiago H.T., Vasey M. Antidepres-sant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behaviour Research and Therapy 2002, 40:67-73.
60. Schwartz J.M., Stoessel P.W., Baxter L.R., Martin K.M., Phelps M.E. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-com-pulsive disorder. Archives of General Psychiatry 1996, 53:109-113.
61. Sharp D.M., Power K.G., Simpson R.J., Swanson V., Moodie E., Anstee J.A., Ashford J.J. Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treat-ment of panic disorder and agoraphobia. Journal of Anxiety Disorders 1996, 10:219-242.
62. Shear M.K., Brown T.A., Barlow D.H., Money R., Sholomskas D.E., Woods S.W., Gorman J.M., Papp L.A. Multicenter collaborative panic disorder severity scale. American Journal of Psychia-try 1997, 154:1571-1575.
63. Spiegel D.A., Bruce T.J. Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: Conclusions from combined treatment trials. American Journal of Psychiatry 1997, 154:773-781.
64. Spiegel D.A., Bruce T.J., Gregg S.F., Nuzzarello A. Does cognitive behavior therapy assist in slow-taper alprazolam discontinuation in panic disorder?. American Journal of Psychiatry 1991, 151:876-881.
65. Stanley M.A., Turner S.M. Current status of pharmacological and behavioral treatment of obsessive-compulsive disorder. Behavior Therapy 1995, 26:163-186.
66. Starcevic V., Linden M., Uhlenhuth E.H., Kolar D., Latas M. Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: Factors influencing psychiatrists' treatment choices. Psychiatry Research 2004, 125:41-52.
67. Stein M.B., Sherbourne C.D., Craske M.G., Means-Christensen A., Bystritsky A., Katon W., Sullivan G., Roy-Byrne P.P. Quality of care for primary care patients with anxiety disorders. Amer-ican Journal of Psychiatry 2004, 161:2230-2237.
68. Swinson R.P., Cox B.J., Woszczyna C.B. Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. Canadian Medical Association Journal 1992, 147:878-883.
69. Telch M.J., Agras W.S., Taylor C.B., Roth W.T., Gallen C. Combined pharmacological and behavioral treatment for agoraphobia. Behaviour Research and Therapy 1985, 23:325-335.
70. van Balkom A.J., de Haan E., van Oppen P., Spinhoven P., Hoogduin K.A., van Dyck R. Cognitive and behavioral therapies alone and in combination with fluvoxamine in the treatment of obsessive-compulsive disorder. Journal of Nervous and Mental Disease 1998, 186:492-499.
71. Westra H.A., Stewart S.H. Cognitive behavioural therapy and pharmacotherapy: Compli-mentary or contradictory approaches to the treatment of anxiety?. Clinical Psychology Review 1998, 18:307-340.
72. Westra H.A., Stewart S.H., Conrad B.E. Naturalistic manner of benzodiazepine use and cog-nitive behavioral therapy outcome in panic disorder with agoraphobia. Journal of Anxiety Disorders 2002, 16:233-246.
73. Whitehead W.E., Blackwell B., Robinson A. Effects of diazepam on phobic avoidance behav-ior and phobic anxiety. Biological Psychiatry 1978, 13:59-64.
74. Whittal M.L., Thordarson D.S., McLean P.D. Treatment of obsessive-compulsive disorder: Cognitive behavior therapy vs. exposure and response prevention. Behaviour Research and Therapy 2005, 43:1559-1576.
75. Zitrin C.M., Klein D., Woerner M.G. Behavior therapy, supportive psychotherapy, imipra-mine, and phobias. Archives of General Psychiatry 1978, 35:303-321.
76. Zitrin C.M., Klein D., Woerner M.G., Ross D.C. Treatment of phobias: Comparison of imipramine hydrochloride and placebo. Archives of General Psychiatry 1983, 40:125-138.